RT Journal Article
SR Electronic
T1 Automated severe aortic stenosis detection on single-view echocardiography: A multi-center deep learning study
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2022.08.30.22279413
DO 10.1101/2022.08.30.22279413
A1 Holste, Gregory
A1 Oikonomou, Evangelos K.
A1 Mortazavi, Bobak J.
A1 Coppi, Andreas
A1 Faridi, Kamil F.
A1 Miller, Edward J.
A1 Forrest, John K.
A1 McNamara, Robert L.
A1 Ohno-Machado, Lucila
A1 Yuan, Neal
A1 Gupta, Aakriti
A1 Ouyang, David
A1 Krumholz, Harlan M.
A1 Wang, Zhangyang
A1 Khera, Rohan
YR 2022
UL http://medrxiv.org/content/early/2022/12/05/2022.08.30.22279413.abstract
AB Background and Aims Early diagnosis of aortic stenosis (AS) is critical to prevent morbidity and mortality but requires skilled examination with Doppler imaging. This study reports the development and validation of a novel deep learning model that relies on 2-dimensional parasternal long axis (PLAX) videos from transthoracic echocardiography (TTE) without Doppler imaging to identify severe AS, suitable for point-of-care ultrasonography.Methods In a training set of 5,257 studies (17,570 videos) from 2016-2020 (Yale-New Haven Hospital [YNHH], Connecticut), an ensemble of 3-dimensional convolutional neural networks was developed to detect severe AS, leveraging self-supervised contrastive pretraining for label-efficient model development. This deep learning model was validated in a temporally distinct set of 2,040 consecutive studies from 2021 from YNHH as well as two geographically distinct cohorts of 5,572 and 865 studies, from California and other hospitals in New England, respectively.Results The deep learning model achieved an AUROC of 0.978 (95% CI: 0.966, 0.988) for detecting severe AS with 95.4% specificity and 90% sensitivity in the temporally distinct test set, maintaining its diagnostic performance in both geographically distinct cohorts (AUROC 0.972 [95% CI: 0.969, 0.975] in California and 0.915 [95% CI: 0.896, 0.933] in New England, respectively). The model was interpretable with saliency maps identifying the aortic valve as the predictive region. Among non-severe AS cases, predicted probabilities were associated with worse quantitative metrics of AS suggesting association with various stages of AS severity.Conclusions This study developed and externally validated an automated approach for severe AS detection using single-view 2D echocardiography, with implications for point-of-care screening.Key Question Is it feasible to automatically screen for the presence of severe aortic stenosis (AS) using single-view echocardiographic videos without the use of Doppler imaging?Key Finding Using self-supervised pretraining and ensemble learning, we trained a deep learning model to detect severe AS using single-view echocardiography without Doppler imaging. The model maintained its high performance in multiple geographically and temporally distinct cohorts.Take-home Message We present an automated method to detect severe AS using single-view TTE videos, with implications for point-of-care ultrasound screening as part of routine clinic visits and in limited resource settings by individuals with minimal training.An automated deep learning approach for severe aortic stenosis detection from single-view echocardiography evaluated across geographically and temporally distinct cohorts.Competing Interest StatementE.K.O is a co-inventor of the U.S. Provisional Patent Application 63/177,117, a co-founder of Evidence2Health, and reports a consultancy and stock option agreement with Caristo Diagnostics Ltd (Oxford, U.K.), all unrelated to the current work. B.J.M. reported receiving grants from the National Institute of Biomedical Imaging and Bioengineering, National Heart, Lung, and Blood Institute, US Food and Drug Administration, and the US Department of Defense Advanced Research Projects Agency outside the submitted work. In addition, B.J.M. has a pending patent on predictive models using electronic health records (US20180315507A1). A.H.R. is supported in part by CNPq (310679/2016-8 and 465518/2014-1) and FAPEMIG (PPM-00428-17 and RED-00081-16) and is funded by Kjell och Märta Beijer Foundation. J.K.F. has received grant support/research contracts and consultant fees/honoraria/Speakers Bureau fees from Edwards Lifesciences and Medtronic. H.M.K. works under contract with the Centers for Medicare & Medicaid Services to support quality measurement programs, was a recipient of a research grant from Johnson & Johnson, through Yale University, to support clinical trial data sharing; was a recipient of a research agreement, through Yale University, from the Shenzhen Center for Health Information for work to advance intelligent disease prevention and health promotion; collaborates with the National Center for Cardiovascular Diseases in Beijing; receives payment from the Arnold & Porter Law Firm for work related to the Sanofi clopidogrel litigation, from the Martin Baughman Law Firm for work related to the Cook Celect IVC filter litigation, and from the Siegfried and Jensen Law Firm for work related to Vioxx litigation; chairs a Cardiac Scientific Advisory Board for UnitedHealth; was a member of the IBM Watson Health Life Sciences Board; is a member of the Advisory Board for Element Science, the Advisory Board for Facebook, and the Physician Advisory Board for Aetna; and is the co-founder of Hugo Health, a personal health information platform, and co-founder of Refactor Health, a healthcare AI-augmented data management company. D.O. is supported by NIH K99 HL157421-01 and has provisional patents in AI and echocardiography. R.K. received support from the National Heart, Lung, and Blood Institute of the National Institutes of Health (under award K23HL153775) and the Doris Duke Charitable Foundation (under award, 2022060). R.K. further receives research support, through Yale, from Bristol-Myers Squibb. He is also a coinventor of U.S. Pending Patent Applications. 63/177,117, and 63/346,610, unrelated to the current work. He is also a founder of Evidence2Health, a precision health platform to improve evidence-based cardiovascular care. The remaining authors have no competing interests to disclose.Funding StatementThe study was supported by the National Heart, Lung, and Blood Institute of the National Institutes of Health (under award K23HL153775 to R.K.).Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:The study was reviewed by the Yale and Cedars-Sinai Institutional Review Boards, which approved the study protocol and waived the need for informed consent as the study represents secondary analysis of existing data.I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesThe data are not available for public sharing given the restrictions in our institutional review board approvals. A deidentified test set may be available to researchers under a data use agreement after the study has been published in a peer-reviewed journal.